ArticleMaedica2026
Prevalence and Predictors of Pulmonary Hypertension in End-Stage Renal Disease: a Single-Center Cross-Sectional Study.
Article in Maedica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pulmonary hypertension (PH) is highly prevalent in patients with chronic kidney disease (CKD) and is a strong predictor of mortality. The relative contributions of vascular access for hemodialysis (HD) in the pathogenesis of PH remain under debate. This study analyses the prevalence and potential predictors of PH in End-stage renal disease (ESRD). Material and methods: A retrospective cross-sectional study of 51 CKD patients on maintenance dialysis (86% HD, 14% peritoneal dialysis (PD)) was conducted. Patients underwent comprehensive echocardiography to estimate systolic pulmonary artery pressure (SPAP). Pulmonary hypertension was defined as SPAP > 35 mm Hg. The associations between SPAP and vascular access type, arteriovenous fistula (AVF) location and echocardiographic parameters were analyzed using univariate and multivariable linear regression models. Results: The prevalence of PH was 31% and the median SPAP was 30 mm Hg. There was no significant difference in SPAP between patients with central venous catheters, proximal AVFs or distal AVFs. Left atrial volume was the strongest independent predictor of SPAP (beta = 0.41, p < 0.001). Elevated E/e' ratio (p = 0.002) and reduced left ventricular ejection fraction (p = 0.016) were significantly associated with SPAP in univariate analysis. PD patients exhibited significantly smaller left atrial volumes compared to HD patients (p = 0.023). Conclusions: Pulmonary hypertension is frequent in ESRD. The main drivers of PH in ESRD are volume overload and left heart disease. These findings support volume management as the primary therapeutic target for PH in the dialysis population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.